# **BMJ Open** Evaluation of emotion-centric psychological interventions for chronic pain: protocol for a systematic review and meta-analysis

Nell Norman-Nott <sup>(1)</sup>, <sup>1,2</sup> Negin Hesam-Shariati <sup>(1)</sup>, <sup>1,2</sup> Aidan G Cashin <sup>(1)</sup>, <sup>2,3</sup> Michael A Wewege <sup>(1)</sup>, <sup>2,3</sup> Rodrigo RN Rizzo <sup>(1)</sup>, <sup>2,3</sup> Chelsey R Wilks <sup>(1)</sup>, <sup>4</sup> Yann Quidé <sup>(1)</sup>, <sup>1,2</sup> James McAuley <sup>(1)</sup>, <sup>2,3</sup> Sylvia Maria Gustin <sup>(1)</sup>, <sup>1,2</sup>

#### ABSTRACT

Introduction Chronic pain, defined as pain persisting longer than 3 months, is more than an unpleasant sensory experience. Persistent negative emotions and emotional comorbidities, such as depression and anxiety, plaque people with chronic pain leading to worsening pain intensity and increasing disability. While cognitive-behavioural therapy (CBT) is the gold standard psychological treatment, recent evidence highlights that CBT lacks efficacy for the physical and emotional aspects of chronic pain. Increasingly, researchers are investigating emotion-centric psychological therapies. While treatment modalities vary, these interventions frequently target understanding emotions, and train individuals for an emotionally adaptive response. The aim of this systematic review and meta-analysis is to quantify the efficacy of emotion-centric interventions for the physical and emotional characteristics of chronic pain.

Methods/analysis Electronic databases (EMBASE, PubMed, PsychINFO, Cochrane Central Register of Controlled Trials, CINAHL and Web of Science) will be systematically searched from inception to 28 April 2022 for randomised controlled trials. Studies that compare an emotion-centric intervention with another form of treatment or placebo/control for adults ( $\geq$ 18 years old) with chronic pain will be included. All treatment modes (eq. online or in-person), any duration and groupbased or individual treatments will be included. Studies that do not investigate at least one emotion-centric treatment will be excluded. The primary outcome is pain intensity. Secondary outcomes include emotion dysregulation, depression, anxiety, affect, safety and intervention compliance. A quantitative synthesis using a random effects meta-analysis will be adopted. Risk of bias will be evaluated using Cochrane Risk of Bias V.2.0 with the certainty of evidence assessed according to Recommendation, Assessment, Development and Evaluation. Data permitting, subgroup analysis will be conducted for intervention type and pain condition. Ethics and dissemination Ethical approval is not required for this systematic review. Results may inform an efficacy study examining a new emotion-centric intervention for chronic pain. Dissemination will be through peer-reviewed publications and in conference presentations.

# STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This systematic review will follow recommendations for conduct and reporting of systematic reviews including independent study selection, data extraction, risk-of-bias assessments by two researchers according to Cochrane Risk of Bias V.2.0, quality of evidence assessed according to Recommendation, Assessment, Development and Evaluation recommendations and reporting according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
- ⇒ To the best of our knowledge, this is the first systemic review and meta-analysis to examine interventions that focus on changing the negative emotional experiences associated with chronic pain.
- ⇒ A meta-analysis may not be possible if there are a lack of comparable studies or interventions, in which case a narrative synthesis is planned.
- ⇒ Findings may be limited by heterogeneity arising from the inclusion of different psychological interventions and different pain conditions or a lack of data.

PROSPERO registration number CRD42021266815.

#### BACKGROUND

Chronic pain, defined as pain persisting **Technologies** longer than 3 months,<sup>1</sup> is a substantial and costly source of suffering. In total, 20% of people live with chronic pain,<sup>2</sup> and annual economic costs to the healthcare system are gestimated to exceed that of heart disease, cancer and diabetes combined.<sup>3</sup> Chronic pain is commonly regarded as being both a sensory and an emotional experience. The International Association for the Study of Pain explains that without emotion, the understanding of chronic pain is incomplete.<sup>4</sup> Research supports this perspective, with fear, anger, worry and low mood frequently reported by people with chronic pain.<sup>5–8</sup>

To cite: Norman-Nott N, Hesam-Shariati N, Cashin AG, *et al.* Evaluation of emotioncentric psychological interventions for chronic pain: protocol for a systematic review and meta-analysis. *BMJ Open* 2022;**12**:e063102. doi:10.1136/ bmjopen-2022-063102

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2022-063102).

Received 24 March 2022 Accepted 28 September 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>NeuroRecovery Research Hub, School of Psychology, University of New South Wales, Sydney, New South Wales, Australia <sup>2</sup>Centre for Pain IMPACT, **Neuroscience Research** Australia, Randwick, New South Wales Australia <sup>3</sup>School of Health Sciences. Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia <sup>4</sup>Department of Psychological Science, University of Missouri, St Louis, Missouri, USA

Correspondence to

Nell Norman-Nott; n.normannott@unsw.edu.au



Beyond negative emotional states, anxiety and depression present in up to 80% of individuals.<sup>9–12</sup> Emotional comorbidities are related to greater suffering, including increased pain intensity and disability,<sup>1314</sup> and are a factor regardless of chronic pain type.<sup>15</sup> Despite the wide acceptance that emotions are key components of chronic pain, the most effective approach to modulate the distressing emotional experience of chronic pain is not yet fully understood.

One mechanism related to negative emotions experienced by people with chronic pain is emotion dysregulation, defined as a heightened sensitivity to emotional stimuli, impeding the ability to identify emotions and to moderate emotional states and expression in line with an adaptive response.<sup>16</sup> Long considered a factor in emotional disorders such as major depression, generalised and social anxiety disorders,<sup>17</sup> emotion dysregulation is now thought to be a crucial factor in the development and the maintenance of chronic pain.<sup>18–20</sup>

The modal model of emotion regulation helps explain emotion dysregulation in the context of chronic pain.<sup>21</sup> According to this model, when an emotion arises due to experiencing an internal or external stimulus, this emotion is then given attention before cognitive appraisal identifies meaning, triggering physiological arousal and a behavioural response.<sup>21</sup> <sup>22</sup> For people with chronic pain, the distress related to their condition impedes self-management abilities, including emotion regulation capabilities.<sup>23</sup> Specifically, the debilitating and distressing aspects of chronic pain, and the experience of missing out (eg, on career, education and social activities), perpetuates negative emotional appraisal of situations, that over time fatigues emotion regulation capabilities.<sup>22-24</sup> With the progression of chronic pain, negative thoughts become more frequent, contributing to increasingly catastrophic perceptions, which perpetuates maladaptive (negative) emotional appraisal.<sup>22</sup> The behavioural result of maladaptive emotional appraisal is hyper-reactivity, meaning too large an emotional response when experiencing a distressing situation, or hyporeactivity, meaning too small an emotional response, or blunted positive emotions, in an emotionally rewarding situation.<sup>25</sup> An absence of positive emotions is a contributing factor for the severity of chronic pain,<sup>26</sup> potentially because positive emotions provide resilience against distressful symptoms and stress.<sup>2</sup>

Emotion dysregulation may also be antecedent to chronic pain, whereby some individuals have a trait-like propensity for emotion dysregulation meaning they are at greater risk of developing chronic pain.<sup>28</sup> <sup>29</sup> Attempts to manage overwhelming emotions have been found to lead to maladaptive emotion regulation strategies (eg, expressive suppression, experiential avoidance and rumination), which are largely counterproductive and lead to a cycle of increasingly intense emotions and worsening chronic pain.<sup>30</sup>

In the treatment of chronic pain, analgesic medication is commonly prescribed to manage painful symptoms.<sup>31</sup>

<page-header><text><text><text><text>

physiotherapists working with chronic pain patients.<sup>50</sup> The results may also be insightful to identify gaps in the literature to provide direction for future studies.

# **OBJECTIVES**

The present systematic review will analyse the evidence from studies that investigate the efficacy of emotioncentric interventions to treat the unpleasant sensory and emotional aspects of chronic pain. We will compare emotion-centric psychological interventions to other types of psychological treatment, treatment-as-usual and control/waitlist. The primary objective is to evaluate the evidence to reduce pain intensity for people with chronic pain. The secondary objective is to evaluate the evidence to improve other factors associated with chronic pain, specifically, emotion dysregulation, depression, anxiety and affect. An additional objective of this review is to narratively report on safety and intervention compliance.

#### **METHODS AND ANALYSIS** Study design

This protocol was written in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for developing review  $protocols^{51}$  (online supplemental appendix 1). The systematic review protocol has been registered with the International Prospective Register of Systematic Reviews (PROSPERO): CRD42021266815.

# **Eligibility criteria**

#### Types of studies

We will include randomised controlled trials (RCTs) that have evaluated the efficacy of emotion-centric interventions delivered online or in-person for any chronic pain condition. This will include emotion-centric interventions compared with treatment-as-usual (standard care waitlist/ no-treatment conditions) and active psychological therapies (eg, CBT, acceptance-commitment therapy (ACT) and mindfulness-based stress reduction (MBSR)). Observational studies and non-randomised trials will be excluded. Additionally, grey literature searches including, research letters, thesis and conferences abstracts will be excluded; however, completed unpublished studies registered in clinical trial registries (eg, ClinicalTrials.gov, EU Clinical Trials Register, ANZ Clinical Trial Registry, WHO International Clinical Trial Registry Platform) will be included.

# Types of participants

We will include studies with adults ( $\geq 18$  years old) with chronic pain, defined as persistent or recurring pain for a minimum of 3 months.<sup>52</sup> All types of chronic pain conditions will be included, because emotions are part of the experience regardless of the chronic pain condition.<sup>15</sup> Chronic pain conditions may include but will not be limited to, rheumatoid arthritis, arthralgia, temporomandibular joint syndrome, myofascial pain, neck pain, back pain, neuralgia, myalgia, myodynia, chronic compartment

, and

syndrome, rheumatic polymyalgia, migraine, headache and fibromyalgia. Studies that enrolled children or adolescents (aged <18 years), and studies enrolling individuals who have been experiencing pain for less than 3 months will be excluded.

#### Types of interventions

We will include emotion-centric psychological intervention regardless of the study mode (eg, internet-delivered, telehealth or face-to-face) and regardless of whether it is group-based or individual. We define emotion-centric interventions as those that help participants understand emotions and teach strategies for an adaptive emotional response. Incorporating emotion regulation skills training from DBT is one such approach that integrates 8 understanding emotions and teaches emotion regulation skills, thus studies administering DBT skills to participants with chronic pain will be included if they also meet the other inclusion criteria.

Studies using psychological interventions that do not focus on helping individuals understand emotions and do not deliver emotional strategies or techniques for effective emotion expression will be excluded. Specifically, MBSR, uses relatec CBT and ACT, when delivered in their standard formats do not purposefully seek to identify emotional reactions and do not typically administer strategies for emotional expression or regulation, so will be excluded.<sup>18 53 54</sup> However, studies which administer MBSR, CBT, ACT or another psychological treatment, adjunct to an emotione centric intervention or emotional targeted strategies will be considered for inclusion. In case of doubt, we will contact corresponding authors to obtain more details on the psychological intervention. Eligible interventions  $\mathbf{\bar{a}}$ may be delivered by a licenced health professional (eg, registered psychologist or physiotherapist), or by a skills trainer in an emotion-centric treatment modality (eg, Al training, DBT skills trainer). If it is unclear, study eligibility will be determined by consensus among reviewers.

### Types of settings

There will be no restriction placed on setting of intervention delivery. For example, studies where the intervention was delivered in primary care, secondary care, universitybased clinics, homes, residential care homes and community settings, including those online will all be included. Types of outcome measures The primary outcome (pain intensity) will be measured **g**.

with validated self-rating instruments (eg, 0-10 Numer- 2 ical Rating Scale (NRS), or a 0-10/0-100 Visual Analogue Scale (VAS)).<sup>55</sup> Studies that use other scales to measure pain intensity will not be excluded, providing they demonstrate psychometric properties for reliability and validity.

Secondary outcomes of interest are, emotion dysregulation (eg, Difficulties in Emotion Regulation Scale), depression (eg, Beck Depression Inventory), anxiety (eg, State-Trait Anxiety Inventory) and affect (eg, Positive and Negative Affect Schedule). Studies that use other scales will not be excluded providing they demonstrate psychometric properties for reliability and validity.

We will consider two outcome assessment timepoints: short-term follow-up, outcome data assessed immediately following the treatment and long-term follow-up, outcome data assessed closest to 3 months, but not longer than 12 months, after the end of treatment. If multiple follow-up data are available for a single timepoint, we will select the last timepoint.

Further secondary outcomes are safety and intervention compliance. Safety is defined as the proportion of participants who experience at least one adverse event during the intervention period. Adverse events are broadly defined as any 'adverse event', 'serious adverse event', 'side effect' or 'complication' resulting in discontinuation of treatment associated with the treatment under investigation (emotion-centric or comparison). Intervention compliance is reflected by the proportion of participants who completed the modules in each study-specific treatment (emotion-centric or comparison) during the intervention period.

# Search strategy

The following databases will be searched for eligible studies: EMBASE (Ovid), Cochrane Central Register of Controlled Trials, Web of Science, PsychInfo, PubMed and CINAHL (EBSCO) (online supplemental appendix 2). Search concepts will include language and keywords for: RCT, chronic pain and terms relating to emotion centric psychological interventions, according to the eligibility criteria defined earlier in the protocol. A search for ongoing trials will be conducted on ClinicalTrials.gov, EU Clinical Trials Register, ANZ Clinical Trial Registry, WHO International Clinical Trial Registry Platform. We will manually search the reference lists of included studies and previous reviews to identify additionally eligible studies. No limitations will be placed on year of publication. Studies written in English, French, German or Persian will be included. While the review is in progress, citation searching for forward citation of recent studies and citation alerts (eg, on Google Scholar) on included studies will be used to identify new studies as they appear. The searches will be rerun prior to the final analysis and further retrieved studies will be included.

## **STUDY SELECTION**

Studies retrieved using the search strategy and those from additional sources will be imported to Covidence,<sup>56</sup> where an automatic deduplication function will be applied to remove duplicate records. Two reviewers (NN-N and NH-S) will independently screen titles and abstracts to determine eligibility and then will conduct full paper reviews. If consensus cannot be reached on eligibility, a third author (YO) will be contacted to resolve through discussion or arbitration. Excluded studies and the reasons for exclusion will be recorded and documented. The search process will be summarised using an adapted PRISMA flow diagram.<sup>57</sup>

# DATA MANAGEMENT AND EXTRACTION

Two reviewers (NN-N and NH-S) will independently extract data from the included studies using a customised data extraction spreadsheet in Microsoft Excel. The form will be pilot tested on two articles. Disagreements will be resolved by consensus or through discussion with a third reviewer (YQ).

# **Study characteristics**

Data about the study characteristics will be extracted, rotected by copyright, including study design, sample size, country, setting, pain condition(s) investigated and duration of the follow-up(s).

# **Participant characteristics**

Data will be extracted about the study sample including age, sex, education, ethnicity, socioeconomic status, duration of pain, comorbidities, and baseline mean and variability for the primary and secondary outcomes. including

#### Interventions and comparators

Data about the intervention and the comparators will be extracted:

- Key components of the psychological intervention, including:
  - Specific details of the psychological approach (eg, CBT plus emotion regulation strategies).
  - Number of sessions.
  - Whether the sessions are group-based or individual.
  - Emotional strategies delivered.
  - Qualifications of personnel delivering the intervention.
- Mode of delivery (eg, online or in-person).
- Intervention frequency and duration.

# **Outcomes**

for uses related to text and data mining, Al Data about the definition for the primary and secondary outcomes investigated will be extracted. Data about the type, dimensions and anchors the measurement tools used to assess the primary and secondary outcomes will also be extracted.

# **Results**

<u>s</u> We will extract data on study results including details of the number of participants randomised to each condition (eg, emotion-centric intervention or compartor). Data will be extracted for the primary outcome of pain inten-Ino sity, and the secondary outcomes of emotion dysregulaĝ tion, depression, anxiety, affect, safety and intervention compliance (including the study-specific definitions of **8** safety and intervention compliance).

The outcomes of safety and intervention compliance will be summarised at a descriptive level because it is expected that these aspects will not be reported in all identified studies and compliance is likely only to be observed in the intervention groups. For all other outcomes, we will preferentially extract the outcome score and measure of variance at the end of treatment (or closest timepoint) for each group and at follow-up, followed by the change

training,

, and

≥

simi

from baseline and measure of variance. Follow-up means the assessment timepoint, which is closest to 3 months after the end of treatment but not longer than 12 months. If data are not available for each trial arm, we will extract the between-group statistics at the end of treatment.

If a study reports more than one measure for pain, we will prioritise the extraction as follows: 100 mm VAS, 10 cm VAS, 11-point NRS, rating on a pain intensity scale for a composite measure (eg, McGill Pain Ouestionnaire), and then rating on an ordinal scale. For all other outcomes, if a given outcome is measured by several measurement tools the hierarchy for analysis will be decided by consensus from the reviewers. Whenever possible, we will use results from an intention-to-treat analysis.<sup>58</sup>

### **Dealing with missing data**

In the case of missing data, the study authors will be contacted where necessary a maximum of three times, after which point it will be considered that the data/ information is irretrievable. If data for the primary or secondary outcomes are not presented in an appropriate form for meta-analysis (eg, median, minimum and maximum values are reported instead of mean and SD). established methods will be considered to impute these values.59

# Assessment of risk of bias

The risk of bias of the included randomised trials will be assessed by two reviewers (NH-S and NN-N) using the Cochrane Risk of Bias (RoB V.2.0) tool for RCTs.<sup>4</sup> According to RoB V.2.0, five domains are evaluated: (a) bias arising from the randomization process; (b) bias due to deviations from intended interventions; (c) bias due to missing outcome data; (d) bias in measurement of the outcome; and (e) bias in selection of the reported results. Risk-of-bias judgement for each domain and an overall judgement can be made in terms of low risk of bias, high risk of bias or some concerns. Reviewers will judge items at the study level, which prioritises information regarding the primary outcome (pain intensity). In case of disagreement, a third reviewer will be consulted (YQ).

#### Assessment of heterogeneity

To assess the extent that the investigated studies are similar, such as they deliver the same emotion-centric intervention, we will assess for heterogeneity using a standard  $\chi^2$  test and will estimate the percentage of the variability that is due to heterogeneity using the  $I^2$  statistic. Heterogeneity will be considered significant when  $p < 0.1 \text{ and } I^2 \ge 50\%$ .<sup>60</sup>

# **DATA SYNTHESIS**

If possible, outcome data extracted from the RCTs will be quantitatively synthesised using a random effects metaanalysis in R (RStudio V.1.2.5033). If a meta-analysis is not possible (due to lack of comparable studies or interventions), a narrative synthesis of the findings will be used to report outcomes according to Synthesis without metaanalysis guidelines.<sup>61</sup>

We plan to conduct two classes of comparisons depending on the comparators used in the studies. First, we will compare emotion-centric intervention to active comparator including other therapies (Active). Second, we will compare emotion-centric intervention to treatment-as-usual including, sham, no treatment and waitlist (TAU). The treatment will be compared at two timepoints, immediately post-treatment (T1), defined as the assessment timepoint occurring at the end of treatment, and at follow-up (T2), defined as the assessment timepoint which is at least 3 months after the end of treatment but not longer than 12 months, and the Z longer follow-up if there were more than one follow-up copyright, including assessment. Therefore, the four separate comparisons are planned as:

- 1. Emotion centric versus Active at T1.
- 2. Emotion centric versus Active at T2.
- 3. Emotion centric versus TAU at T1.
- 4. Emotion centric versus TAU at T2.

For each comparison, the primary outcome data (pain intensity) will be converted to a common 0-100 point uses rela scales (mean and SD).<sup>62</sup> For numerical and continuous scales, the score value will be divided by the range of scale, and then multiplied by 100. For example, for a 0 to 20 scale, the score value will be divided by 20 and multiplied by 100. We plan to use a weighted mean difference ç with 95% CI.

For the secondary outcome data (emotion dysregulation, depression, anxiety and affect) standardised mean differences (SMD), with 95% CI, will be computed to obtain a summary measure of effect size across the studies to quantify the impact of treatment relative to Active **B** or TAU for each comparison. By using an SMD for the secondary outcomes, we will be able to synthesise across data measuring the same outcomes (eg, depression) but with different scales.<sup>60</sup>

tih different scales.<sup>60</sup> Binary outcome data based on clinical improvement re rare,<sup>37</sup> but if they exist (eg, for pain intensity) we will are rare,<sup>37</sup> but if they exist (eg, for pain intensity) we will and calculate relative risk with 95% CI for binary outcomes.

We will classify the magnitude of the effect as small/ slight, moderate or large/substantial in accordance with definitions provided by the American Pain Society<sup>63</sup> for the primary outcome (pain intensity), and according to technologies Cohen,<sup>64</sup> for the secondary outcomes (emotion dysregulation, depression, anxiety and affect) (table 1).

#### **CERTAINTY OF EVIDENCE**

Two reviewers (NH-S and NN-N) will assess the evidence for each of the outcomes based on the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach.<sup>65</sup> For each GRADE domain, the evidence will be rated according to the level of certainty of an intervention effect: high, we are very certain that the true effect of the intervention is close to the estimate of the effect; moderate, we are moderately certain that

Table 1 Definitions for magnitude of the effects, based on mean between-group differences 63 64 74

-		
Slight/small	Moderate	Large/substantial
Pain intensity		
5–10 points on a 0–100-point VAS or equivalent	>10–20 points on a 0–100-point VAS or equivalent	>20 points on a 0–100-point VAS or equivalent
0.5–1.0 points on a 0–10-point NRS or equivalent	>1–2 points on a 0–10-point NRS or equivalent	>2 points on a 0–10-point NRS or equivalent
Function*		
0.2-0.5 SMD	>0.5-0.8 SMD	>0.8 SMD
*Function includes the secondary outcomes of emotion		

dysregulation, depression and anxiety.

NRS, Numeric Rating Scale; SMD, standard mean difference; VAS, Visual Analogue Scale.

the estimate of the effect is close to the true effect; low, we have limited certainty that the estimate of the effect represents the true effect; very low, we have very little certainty in the effect estimate and the true effect is likely to be substantially different.

We limit the inclusion of studies to RCTs which according to GRADE are classified as high. Evidence of an effect will be downgraded using the following criteria:

#### **Risk of bias**

The rating will be downgraded by one level if more than 25% (but less than 50%) of participants are from studies with a high risk of bias, and will be downgraded by two levels if more than 50% of participants are from studies with high risk of bas.<sup>66</sup>

# Inconsistency

The rating will be downgraded by one level if significant heterogeneity is identified (p<0.1) and variability is substantial  $(I^2 \ge 50\%)$ .<sup>67</sup>

#### Imprecision

The rating will be downgraded by one level if the optimal information size is not met (>400). If the optimal information size is met, the rating will be downgraded by one level if CIs are wide. For example, for continuous outcomes, there is a 20-point difference to the point estimate; that is, two times the minimal clinically important difference of 10 points on a 100-point scale, and for dichotomous measures if the lower or upper limits of the 95% CI include appreciable benefit or harm (ie, 95% CI under 0.75 or over 1.25) level.<sup>68</sup>

#### **Publication bias**

Publication bias will be evaluated using conventional funnel plots to examine publication asymmetry, potentially indicative of publication bias<sup>69</sup> and contour-enhanced funnel plots to judge whether the results of studies cluster around nominal thresholds for statistical significance, potentially indicative of data dredging/p-hacking.<sup>70</sup>

tex

Where>10 studies are available in a funnel plot, we will also conduct Egger's regression test for statistical assessment of publication asymmetry (with  $\alpha < 0.10$  indicating the presence of asymmetry).<sup>71</sup> The rating will be downgraded by one level if the funnel plot suggests the presence of publication bias.<sup>72</sup>

The GRADE domain of indirectness will not be assessed because the inclusion criteria will help determine sufficient similarity of participants, interventions and comparators across studies.<sup>7</sup>

### SUBGROUP AND SENSITIVITY ANALYSIS

Protected If significant heterogeneity is present (p<0.1), by treatby copy ment type (eg, emotion-centric intervention), and pain condition (eg, low back pain, facial pain), a subgroup analysis will be performed.

/right, A sensitivity analysis will also be conducted excluding studies with a high risk of bias.

studies with a high risk of bias. **PATIENT AND PUBLIC INVOLVEMENT** No patient involved. **DISCUSSION** Evidence widely supports the presence of pervasive and distressing emotions as a key feature of chronic pain.<sup>4-7</sup> These emotional problems lead to heightened suffering and disability.<sup>13 14</sup> While pharmacological medications are and disability.<sup>1314</sup> While pharmacological medications are commonly prescribed for people with chronic pain symp-toms, there is little effect on emotional problems.<sup>10 35</sup> Moreover, recent evidence indicates that CBT, the gold standard in psychological treatment for chronic pain, has limited efficacy for both the physical and emotional aspects.<sup>37</sup> Increasingly, researchers are developing and testing new and adjunct emotion-centric psychological treatments.<sup>23 40-42</sup> While findings are promising, a firm conclusion cannot yet be determined about the  $\geq$ extent that emotion-centric interventions are effective for chronic pain symptoms. Results from this systematic review and meta-analysis will be a step towards closing this knowledge gap. Findings may be insightful for psychologists and clinicians, including physiotherapists working with people with chronic pain. For example, if the findings are supportive of emotion-centric interventions compared with other treatment modalities then there is evidence for clinical psychologists to use more emotionally centric treatment strategies for their clients with chronic pain. Similarly, this review will report the adverse events for such emotion-centric interventions, which is 5 important to understand the safety of implementation in clinical practice.

#### **ETHICS AND DISSEMINATION**

Ethical approval is not required for this systematic review. Results may inform an efficacy study examining a new emotion-centric intervention for chronic pain. Dissemination will be through peer-reviewed publications and in conference presentations.

Twitter Nell Norman-Nott @NellNormanNott, Aidan G Cashin @AidanCashin, Rodrigo RN Rizzo @rodrizzo\_pain and Sylvia Maria Gustin @SylviaGustin2

**Contributors** NN-N, and SMG conceptualised this protocol. NN-N, NH-S, AGC, MW, RRNR, CRW, YQ, JM and SMG defined the concepts, search items, data extraction process and methodological appraisal of the studies. NN-N drafted the manuscript, and all authors critically reviewed and revised the manuscript for important intellectual content. All authors have approved the final manuscript. All authors agree to be accountable for all aspects of the work, and to ensure that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors have approved the final manuscript for publication.

**Funding** This work was supported by a Rebecca Cooper Fellowship from the Rebecca L. Cooper Medical Research Foundation awarded to Sylvia M. Gustin. Nell Norman-Nott was supported by the Australian Government Research Training Program (RTP) Scholarship (administered by the University of New South Wales), a supplementary scholarship and the PhD Pearl Award administered by Neuroscience Research Australia (NeuRA). Negin Hesam-Shariati was supported by a postdoctoral fellowship from the Craig H. Neilsen Foundation. Rodrigo RN Rizzo was supported by the University of New South Wales School of Medical Sciences Postgraduate Research Scholarship and a NeuRA PhD Candidature Supplementary Scholarship. Michael A Wewege was supported by a Postgraduate School of Medical Sciences Top-Up Scholarship from the University of New South Wales, and a supplementary scholarship administered by NeuRA. The funding bodies had no role in the decision to publish this protocol.

**Competing interests** CRW receives consulting fees from Mindstrong Health, Behavioral Tech and Lyra Health.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

#### **ORCID iDs**

Nell Norman-Nott http://orcid.org/0000-0002-0084-1454 Negin Hesam-Shariati http://orcid.org/0000-0003-0829-7016 Aidan G Cashin http://orcid.org/0000-0003-4190-7912 Michael A Wewege http://orcid.org/0000-0002-3283-2149 Rodrigo RN Rizzo http://orcid.org/0000-0002-9624-6210 Chelsey R Wilks http://orcid.org/0000-0002-9604-6210 Chelsey R Wilks http://orcid.org/0000-0002-9604-6305 Yann Quidé http://orcid.org/0000-0002-8569-7139 James McAuley http://orcid.org/0000-0002-0550-828X Sylvia Maria Gustin http://orcid.org/0000-0002-9613-9845

#### REFERENCES

- 1 IASP. Part III Pain Terms. In: Merskey H, Bogduk N, eds. *Classification of chronic pain: IASP*, 2011.
- 2 Blyth FM, March LM, Brnabic AJ, *et al*. Chronic pain in Australia: a prevalence study. *Pain* 2001;89:127–34.
- 3 Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain 2012;13:715–24.
- 4 ed.Merskey H, Bogduk N. *Classification of chronic pain : descriptions of chronic pain syndromes and definitions of pain terms*. 2nd. Seattle: IASP Press, 1994.

- 5 Eccleston C, Crombez G. Worry and chronic pain: a misdirected problem solving model. *Pain* 2007;132:233–6.
- 6 Vlaeyen JWS, Linton SJ. Fear-avoidance model of chronic musculoskeletal pain: 12 years on. *Pain* 2012;153:1144–7.
- 7 Trost Z, Vangronsveld K, Linton SJ, et al. Cognitive dimensions of anger in chronic pain. Pain 2012;153:515–7.
- 8 Craig A, Tran Y, Siddall P, *et al*. Developing a model of associations between chronic pain, depressive mood, chronic fatigue, and self-efficacy in people with spinal cord injury. *J Pain* 2013;14:911–20.
- 9 Asmundson GJG, Katz J. Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-art. *Depress Anxiety* 2009;26:888–901.
- 10 Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433–45.
- 11 Bair MJ, Wu J, Damush TM, *et al.* Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. *Psychosom Med* 2008;70:890–7.
- 12 Sheng J, Liu S, Wang Y, *et al*. The link between depression and chronic pain: neural mechanisms in the brain. *Neural Plast* 2017;2017:9724371.
- 13 Bair MJ, Poleshuck EL, Wu J, et al. Anxiety but not social stressors predict 12-month depression and pain severity. Clin J Pain 2013;29:95–101.
- 14 Lerman SF, Rudich Z, Brill S, et al. Longitudinal associations between depression, anxiety, pain, and pain-related disability in chronic pain patients. *Psychosom Med* 2015;77:333–41.
- 15 Gustin SM, Wilcox SL, Peck CC, et al. Similarity of suffering: equivalence of psychological and psychosocial factors in neuropathic and non-neuropathic orofacial pain patients. Pain 2011;152:825–32.
- 16 Gratz KL, Roemer L. Multidimensional assessment of emotion regulation and dysregulation: development, factor structure, and initial validation of the difficulties in emotion regulation scale. J Psychopathol Behav Assess 2004;26:41–54.
- 17 Mennin DS, Holaway RM, Fresco DM, et al. Delineating components of emotion and its dysregulation in anxiety and mood psychopathology. *Behav Ther* 2007;38:284–302.
- 18 Lumley MA, Cohen JL, Borszcz GS, et al. Pain and emotion: a biopsychosocial review of recent research. J Clin Psychol 2011;67:942–68.
- 19 Baker KS, Gibson S, Georgiou-Karistianis N, et al. Everyday executive functioning in chronic pain: specific deficits in working memory and emotion control, predicted by mood, medications, and pain interference. *Clin J Pain* 2016;32:673–80.
- 20 Trucharte A, Leon L, Castillo-Parra G, et al. Emotional regulation processes: influence on pain and disability in fibromyalgia patients. *Clin Exp Rheumatol* 2020;38 Suppl 123:40–6.
- 21 Gross JJ. The extended process model of emotion regulation: Elaborations, applications, and future directions. *Psychological Inquiry* 2015;26:130–7.
- 22 Koechlin H, Coakley R, Schechter N, et al. The role of emotion regulation in chronic pain: a systematic literature review. J Psychosom Res 2018;107:38–45.
- 23 Russell BS, Park CL. The role of emotion regulation in chronic pain self-management. *Topics in Pain Management* 2018;33.
- 24 Vos T, Barber RM, Bell B. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. *The Lancet* 2015;386:743–800.
- 25 Berenbaum H, Raghavan C LH-N, et al. A taxonomy of emotional disturbances. Clinical Psychology: Science and Practice 2003;10:206–26.
- 26 Finan PH, Garland EL. The role of positive affect in pain and its treatment. *Clin J Pain* 2015;31:177–87.
- 27 Ong AD, Bergeman CS, Bisconti TL, et al. Psychological resilience, positive emotions, and successful adaptation to stress in later life. J Pers Soc Psychol 2006;91:730–49.
- 28 Gustin SM, Burke LA, Peck CC, et al. Pain and personality: do individuals with different forms of chronic pain exhibit a mutual personality? Pain Pract 2016;16:486–94.
- 29 Naylor B, Hesam-Shariati N, McAuley JH, et al. Reduced glutamate in the medial prefrontal cortex is associated with emotional and cognitive dysregulation in people with chronic pain. *Front Neurol* 2019;10:1110.
- 30 Wenzlaff RM, Wegner DM. Thought suppression 2000;51:59–91.
- 31 Finnerup NB, Attal N, Haroutounian S, *et al.* Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol* 2015;14:162–73.
- 32 Turk DC, McCarberg B. Non-Pharmacological treatments for chronic pain. *Disease Management & Health Outcomes* 2005;13:19–30.

# **Open access**

- 33 Edlund MJ, Martin BC, Russo JE, et al. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. *Clin J Pain* 2014;30:557–64.
- 34 Ray WA, Chung CP, Murray KT, *et al.* Prescription of long-acting opioids and mortality in patients with chronic noncancer pain. *JAMA* 2016;315:2415–23.
- 35 Linton SJ, Bergborn S. Understanding the link between depression and pain. *Scand J Pain* 2011;2:47–54.
- 36 Hassett AL, Williams DA. Non-Pharmacological treatment of chronic widespread musculoskeletal pain. Best Pract Res Clin Rheumatol 2011;25:299–309.
- 37 Williams ACdeC, Fisher E, Hearn L, et al. Psychological therapies for the management of chronic pain (excluding headache) in adults. *Cochrane Database Syst Rev* 2020;8:CD007407.
- 38 Basler HD, Jäkle C, Kröner-Herwig B. Incorporation of cognitivebehavioral treatment into the medical care of chronic low back patients: a controlled randomized study in German pain treatment centers. *Patient Educ Couns* 1997;31:113–24.
- 39 Alda M, Luciano JV, Andrés E, *et al.* Effectiveness of cognitive behaviour therapy for the treatment of catastrophisation in patients with fibromyalgia: a randomised controlled trial. *Arthritis Res Ther* 2011;13:R173.
- 40 Kleinstäuber M, Allwang C, Bailer J, et al. Cognitive behaviour therapy complemented with emotion regulation training for patients with persistent physical symptoms: a randomised clinical trial. *Psychother Psychosom* 2019;88:287–99.
- 41 Lumley MA, Schubiner H, Williams D. Emotional awareness and expression therapy for chronic pain: outcomes and emotion-focused moderators. *Psychosom Med* 2019;81:A191.
- 42 Boersma K, Södermark M, Hesser H, et al. Efficacy of a transdiagnostic emotion-focused exposure treatment for chronic pain patients with comorbid anxiety and depression: a randomized controlled trial. *Pain* 2019;160:1708–18.
- 43 Linehan MM, Wilks CR. The course and evolution of Dialectical behavior therapy. *Am J Psychother* 2015;69:97–110.
- 44 Bernardy K, Klose P, Busch AJ, et al. Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst Rev 2013;2017.
- 45 Prothero L, Barley E, Galloway J, et al. The evidence base for psychological interventions for rheumatoid arthritis: a systematic review of reviews. *Int J Nurs Stud* 2018;82:20–9.
- 46 Jackson W, Zale EL, Berman SJ, et al. Physical functioning and mindfulness skills training in chronic pain: a systematic review. J Pain Res 2019;12:179–89.
- 47 Hilton L, Hempel S, Ewing BA, et al. Mindfulness meditation for chronic pain: systematic review and meta-analysis. Ann Behav Med 2017;51:199–213.
- 48 Simpson PA, Mars T, Esteves JE. A systematic review of randomised controlled trials using acceptance and commitment therapy as an intervention in the management of non-malignant, chronic pain in adults. *International Journal of Osteopathic Medicine* 2017;24:18–31.
- 49 Abbass A, Lumley MA, Town J, et al. Short-Term psychodynamic psychotherapy for functional somatic disorders: a systematic review and meta-analysis of within-treatment effects. J Psychosom Res 2021;145:110473.
- 50 Alexanders J, Anderson A, Henderson S. Musculoskeletal physiotherapists' use of psychological interventions: a systematic review of therapists' perceptions and practice. *Physiotherapy* 2015;101:95–102.
- 51 Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
- 52 Treede R-D, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. Pain 2015;156:1003–7.
- 53 Maroti D, Ek J, Widlund R-M, *et al.* Internet-Administered emotional awareness and expression therapy for somatic symptom disorder

with centralized symptoms: a preliminary efficacy trial. *Front Psychiatry* 2021;12:620359.

- 54 Lumley MA, Schubiner H. Psychological therapy for centralized pain: an integrative assessment and treatment model. *Psychosom Med* 2019;81:114–24.
- 55 Jensen MP, Karoly P. Self-Report scales and procedures for assessing pain in adults. Handbook of pain assessment. New York: Guildford Press, 1993: 15–34.
- 56 Innovation VH. Covidence systematic review software: Covidence. Available: https://www.covidence.org [Accessed 06/09/2021].
- 57 Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
- 58 Fergusson D, Aaron SD, Guyatt G, et al. Post-Randomisation exclusions: the intention to treat principle and excluding patients from analysis. *BMJ* 2002;325:652–4.
- 59 Wan X, Wang W, Liu J, *et al.* Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014;14:135.
- 60 Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for systematic reviews of interventions version 6.0, 2019.
- 61 Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (swim) in systematic reviews: reporting guideline. BMJ 2020;368:I6890.
- 62 Busse JW, Bartlett SJ, Dougados M. Optimal strategies for reporting pain in clinical trials and systematic reviews: recommendations from an OMERACT 12 workshop. *The Journal of Rheumatology* 1962;2015;42.
- 63 Chou R, Qaseem A, Snow V. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of physicians and the American pain Society. *Annals of Internal Medicine* 2007;147:478–91.
- 64 Cohen J. Statistical power analysis for the behavioral sciences. 2nd. Routledge, 1988.
- 65 Guyatt G, Oxman AD, Akl EA. Grade guidelines: 1. Introduction GRADE evidence profiles and summary of findings tables. *Journal of Clinical Epidemiology* 2011;64:383–94.
- 66 Guyatt GH, Oxman AD, Vist G. GRADE guidelines: 4. Rating the quality of evidence - risk of bias. *Journal of Clinical Epidemiology* 2011;64:407–15.
- 67 Guyatt GH, Oxman AD, Kunz R. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. *Journal of Clinical Epidemiology* 2011;64:1294–302.
- 68 Guyatt GH, Oxman AD, Kunz R. GRADE guidelines 6. Rating the quality of evidence - imprecision. *Journal of Clinical Epidemiology* 2011;64:1283–93.
- 69 Sterne JAC, Sutton AJ, Ioannidis JPA. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;343:d4002.
- 70 Peters JL, Sutton AJ, Jones DR. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. *Journal of Clinical Epidemiology* 2008;61:991–6.
- 71 Egger M, Smith GD, Schneider M. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629.
- 72 Guyatt GH, Oxman AD, Montori V. GRADE guidelines: 5. Rating the quality of evidence - ;publication bias. *Journal of Clinical Epidemiology* 2011;64:1277–82.
- 73 Guyatt GH, Oxman AD, Kunz R. Grade guidelines: 8. rating the quality of evidence—indirectness. *Journal of Clinical Epidemiology* 2011;64:1303–10.
- 74 RWJG O, Deyo RA, Stratford P. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. *Spine* 2008;33.